SkinCancer360

Checkpoint Therapeutics Receives Approval for PD-L1 Therapy
Featured image for “Checkpoint Therapeutics Receives Approval for PD-L1 Therapy”

Checkpoint Therapeutics Receives Approval for PD-L1 Therapy

December 16, 2024
The approval of cosibelimab-ipdl provides an option for patients with cutaneous squamous cell carcinoma December 13, 2024 (Sacramento, California) The…
[wpb_childpages]

Recent Posts

Featured image for “Cutaneous Squamous Cell Carcinoma is Exploding Among U.S. Males Over 65”
Jun. 07, 2025

Cutaneous Squamous Cell Carcinoma is Exploding Among U.S. Males Over 65

Featured image for “Trial Result Confirms the Advantage of Cemiplimab for Skin Cancer at High Risk of Recurrence”
Jun. 03, 2025

Trial Result Confirms the Advantage of Cemiplimab for Skin Cancer at High Risk of Recurrence

Featured image for “What’s New in Clinical Trials for Cutaneous Squamous Cell Carcinoma?”
May. 28, 2025

What’s New in Clinical Trials for Cutaneous Squamous Cell Carcinoma?

Featured image for “Wide Local Excision vs. Mohs Surgery: A Dermatologist Explains”
Apr. 23, 2025

Wide Local Excision vs. Mohs Surgery: A Dermatologist Explains

Featured image for “Skin Cancer Risk Persists for 30 Years after Blood Cancer Diagnosis”
Mar. 31, 2025

Skin Cancer Risk Persists for 30 Years after Blood Cancer Diagnosis

Post Categories